Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration

References

• Van Zeeburg EJT, Van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2012;229(1):1–14. doi:10.1159/000343066
   PubMed Web of Science ®Google Scholar
• Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990;109(1):33–37. doi:10.1016/S0002-9394(14)75575-8
   PubMed Web of Science ®Google Scholar
• Tennant MTS, Borrillo JL, Regillo CD. Management of submacular hemorrhage. Ophthalmol Clin North Am. 2002;15(4):445–452. doi:10.1016/S0896-1549(02)00049-4
   Google Scholar
• Buschini E, Iannetta D, Lesnik Oberstein SY, Bijl HM, Mura M. Subretinal versus intravitreal injection of recombinant tissue plasminogen activator in post-traumatic submacular haemorrhages. Acta Ophthalmol. 2016;94(3):307–309. doi:10.1111/aos.12816
   Web of Science ®Google Scholar
• Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109(5):723–729. doi:10.1001/archopht.1991.01080050139046
   PubMedGoogle Scholar
• Hattenbach LO, Klais C, Koch FHJ, Gümbel HOC. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108(8):1485–1492. doi:10.1016/S0161-6420(01)00648-0
   PubMed Web of Science ®Google Scholar
• Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16(3):183–189. doi:10.1097/00006982-199616030-00001
   PubMed Web of Science ®Google Scholar
• Gillies A, Lahav M. Absorption of retinal and subretinal hemorrhages. Ann Ophthalmol. 1983;15(11):1068–1074.
   PubMedGoogle Scholar
• Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94(6):762–773. doi:10.1016/0002-9394(82)90301-4
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/nejmoa054481
   PubMed Web of Science ®Google Scholar
• Chen CY, Hooper C, Chiu D, Chamberlain M, Karia N, Heriot WJ. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina. 2007;27(3):321–328. doi:10.1097/01.iae.0000237586.48231.75
   PubMed Web of Science ®Google Scholar
• Haupert CL, Mccuen BW, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131(2):208–215. doi:10.1016/S0002-9394(00)00734-0
   PubMed Web of Science ®Google Scholar
• Olivier S, Chow DR, Packo KH, MacCumber MW, Awh CC. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology. 2004;111(6):1201–1208. doi:10.1016/j.ophtha.2003.10.020
   PubMed Web of Science ®Google Scholar
• Chang W, Garg SJ, Maturi R, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol. 2014;157(6):1250–1257. doi:10.1016/j.ajo.2014.02.007
   PubMed Web of Science ®Google Scholar
• Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116(10):1326–1332. doi:10.1001/archopht.116.10.1326
   PubMedGoogle Scholar
• Tsymanava A, Uhlig CE. Intravitreal recombinant tissue plasminogen activator without and with additional gas injection in patients with submacular haemorrhage associated with age-related macular degeneration. Acta Ophthalmol. 2012;90(7):633–638. doi:10.1111/j.1755-3768.2011.02115.x
   Web of Science ®Google Scholar
• Peyman GA, Nelson NC, Alturki W, et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg. 1991;22(10):575–582.
   Google Scholar
• Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol. 1996;121(3):267–275. doi:10.1016/S0002-9394(14)70274-0
   Web of Science ®Google Scholar
• Martel JN, Mahmoud TH. Subretinal pneumatic displacement of subretinal hemorrhage. JAMA Ophthalmol. 2013;131(12):1632–1635. doi:10.1001/jamaophthalmol.2013.5464
   PubMed Web of Science ®Google Scholar
• Kadonosono K, Arakawa A, Yamane S, et al. Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology. 2015;122(1):123–128. doi:10.1016/j.ophtha.2014.07.027
   PubMed Web of Science ®Google Scholar
• Fassbender JM, Sherman MP, Barr CC, Schaal S. Tissue plasminogen activator for subfoveal hemorrhage due to age-related macular degeneration. Retina. 2016;36(10):1860–1865. doi:10.1097/IAE.0000000000001030
   PubMed Web of Science ®Google Scholar
• Lee K, Park YG, Park YH. Visual prognosis after pneumatic displacement of submacular hemorrhage according to age-related macular degeneration subtypes. Retina. 2020;40(12):2304–2311. doi:10.1097/IAE.0000000000002762
   Web of Science ®Google Scholar
• Benner JD, Hay A, Landers MB, Hjelmeland LM, Morse LS. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology. 1994;101(4):672–681. doi:10.1016/S0161-6420(94)31279-6
   Web of Science ®Google Scholar
• Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287–290. doi:10.1016/j.jcrs.2004.01.014
   PubMed Web of Science ®Google Scholar
• Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010;4(1):67–72. doi:10.2147/opth.s8635
   Google Scholar
• Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. 2010;94(1):48–53. doi:10.1136/bjo.2009.164707
   PubMed Web of Science ®Google Scholar
• Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96(5):708–713. doi:10.1136/bjophthalmol-2011-300655
   PubMed Web of Science ®Google Scholar
• Ron Y, Ehrlich R, Axer-Siegel R, Rosenblatt I, Weinberger D. Pneumatic displacement of submacular hemorrhage due to age-related macular degeneration. Ophthalmologica. 2006;221(1):57–61. doi:10.1159/000096524
   Web of Science ®Google Scholar
• Gopalakrishan M, Giridhar A, Bhat S, Saikumar SJ, Elias A. Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection. Retina. 2007;27(3):329–334. doi:10.1097/01.iae.0000231544.43093.40
   PubMed Web of Science ®Google Scholar
• Fujikawa M, Sawada O, Miyake T, et al. Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina. 2013;33(9):1908–1914. doi:10.1097/IAE.0b013e318287d99d
   PubMed Web of Science ®Google Scholar
• Georgalas I, Papaconstantinou D, Karagiannis D, Ladas I. Pneumatic displacement of acute submacular hemorrhage with and without the use of tPA. Eur J Ophthalmol. 2011;21(2):220. doi:10.5301/ejo.2010.5685
   Web of Science ®Google Scholar
• Mizutani T, Yasukawa T, Ito Y, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249(8):1153–1157. doi:10.1007/s00417-011-1649-1
   Web of Science ®Google Scholar
• Hillenkamp J, Surguch V, Framme C, Gabel VP, Sachs HG. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248(1):5–11. doi:10.1007/s00417-009-1158-7
   PubMed Web of Science ®Google Scholar
• Kishikova L, Saad AAA, Vaideanu-Collins D, Isac M, Hamada D, El-Haig WM. Comparison between different techniques for treatment of submacular haemorrhage due to age-related macular degeneration. Eur J Ophthalmol. 2020;112067212095955. doi:10.1177/1120672120959551
   Web of Science ®Google Scholar
• Avcı R, Yıldız AM, Çınar E, et al. Subretinal coapplication of tissue plasminogen activator and bevacizumab with concurrent pneumatic displacement for submacular hemorrhages secondary to neovascular age-related macular degeneration. Turk J Ophthalmol. 2021;51(1):38–44. doi:10.4274/tjo.galenos.2020.72540
   Google Scholar
• Maggio E, Deiro AP, Mete M, et al. Intravitreal recombinant tissue plasminogen activator and sulphur hexafluoride gas for submacular haemorrhage displacement in age-related macular degeneration: looking behind the blood. Res Artic Ophthalmol. 2020;243:224–235. doi:10.1159/000505752
   Web of Science ®Google Scholar
• Meyer CH, Scholl HP, Eter N, Helb HM, Holz FG. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008;86(5):490–494. doi:10.1111/j.1600-0420.2007.01125.x
   PubMed Web of Science ®Google Scholar
• Sacu S, Stifter E, Vécsei-Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye. 2009;23(6):1404–1410. doi:10.1038/eye.2008.267
   PubMed Web of Science ®Google Scholar
• Guthoff R, Guthoff T, Meigen T, Goebel W. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. 2011;31(1):36–40. doi:10.1097/IAE.0b013e3181e37884
   PubMed Web of Science ®Google Scholar
• Mayer WJ, Hakim I, Haritoglou C, et al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol. 2013;91(3):274–278. doi:10.1111/j.1755-3768.2011.02264.x
   Web of Science ®Google Scholar
• Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. 2017;13(12):1217–1224. doi:10.1080/17425255.2017.1404987
   PubMed Web of Science ®Google Scholar